Fudan University: Brain Neoplasms trials

The registry lists 16 Brain Neoplasms studies with Fudan University as lead sponsor. 10 are open to participants now and 0 have results posted.

Phase 1 3Phase 2 13No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Sac-TMT Combined With Bevacizumab in TNBC With Brain MetastasesRecruitingNCT07623577Phase 2
• Risk and Prognosis of Brain Metastasis in Non-Small Cell Lung CancerNot yet recruitingNCT07034365
• Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast CancerNot yet recruitingNCT06797622Phase 2
• BrAin Metastasis in TripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADCRecruitingNCT06793332Phase 2
• Study of SHR-A1811 Combined with Pyrotinib and Bevacizumab in Advanced Breast Cancer with Brain MetastasisRecruitingNCT06718933Phase 1/2
• AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain MetastasesRecruitingNCT06604689
• Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain MetastasisRecruitingNCT06501391Phase 2
• WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain MetastasesRecruitingNCT06243003Phase 1/2
• SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain MetastasesNot yet recruitingNCT06210438Phase 2
• A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain MetastasesNot yet recruitingNCT06088056Phase 2
• Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain MetastasesActive, not recruitingNCT07491211
• SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKIActive, not recruitingNCT06020066Phase 2
• ARX788 in HER2-positive Breast Cancer Patients With Brain MetastasesStatus unknownNCT05018702Phase 2
• Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain MetastasesStatus unknownNCT04582968Phase 1/2
• FSRT in Breast Cancer Patients With Brain MetastasesStatus unknownNCT04061408Phase 2
• X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain MetastasesActive, not recruitingNCT03753685Phase 2